Angola vs Lesotho: HIV/AIDS deaths averted by antiretroviral therapy
Angola
14,494 deaths
in 2024
Lesotho
16,464 deaths
in 2024
Angola rank
16th
Lesotho rank
15th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Angola
- Lesotho
How they compare
Lesotho currently reports 16,464 deaths against 14,494 deaths in Angola, a difference of 1,970 deaths.
That makes Lesotho's figure about 1.1 times Angola's.
Across all 35 years both countries report, Lesotho has been ahead every year.
Angola ranks 16th and Lesotho ranks 15th of 157 countries.
Lesotho has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Angola | Lesotho | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 765.87 deaths | 3,511 deaths | 2,745 deaths | Lesotho |
| 2010s | 7,024 deaths | 15,323 deaths | 8,299 deaths | Lesotho |
| 2020s | 12,363 deaths | 17,301 deaths | 4,938 deaths | Lesotho |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Angola or Lesotho?
- Lesotho, at 16,464 deaths against 14,494 deaths in Angola as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Angola and Lesotho?
- 1,970 deaths, with Lesotho ahead.
- How many years of comparable data are there for Angola and Lesotho?
- 35 years are reported by both, from 1990 to 2024.
- How do Angola and Lesotho rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Angola ranks 16th and Lesotho ranks 15th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.